# Angèle Maki

> Angèle Maki, PhD, is a biopharmaceutical business development executive with more than 20 years of deal-making across emerging biotechs and global pharma. In December 2025 she became the first Chief Business Officer of Ability Biotherapeutics, a Montreal-based company building logic-gated antibodies with its generative-AI platform AbiLeap. A Stanford-trained biological chemist who started at the University of Winnipeg, she has held senior roles at Medarex, Bristol Myers Squibb, Genentech, 23andMe, Merck, Eli Lilly, ReCode Therapeutics and Callio Therapeutics, and chairs the non-profit Canadian Entrepreneurs in Life Sciences.

- **Role:** Chief Business Officer at Ability Biotherapeutics
- **Organizations:** Ability Biotherapeutics, Callio Therapeutics, ReCode Therapeutics, Eli Lilly and Company, Merck & Co., 23andMe, Genentech, Bristol Myers Squibb, Medarex, Canadian Entrepreneurs in Life Sciences (CELS)
- **Nationality:** Canadian
- **Education:** B.Sc. in Chemistry, University of Winnipeg, Ph.D. in Biological Chemistry, Stanford University, Postdoctoral research in Molecular Biology, The Scripps Research Institute, La Jolla, CA
- **Known for:** Appointed the first Chief Business Officer of Ability Biotherapeutics in December 2025, Led or supported numerous in- and out-licensing transactions from early-stage research technologies to clinical-stage assets, Held business development and corporate venture leadership roles across both emerging biotechs and global pharma over 20+ years

## Career timeline

- **Early career** — Business development roles at Medarex, later part of Bristol Myers Squibb
- **—** — Business development leadership at Genentech, 23andMe and Merck & Co.
- **—** — Vice President, Venture Science, Corporate Business Development at Eli Lilly and Company
- **2021** — Appointed Senior Vice President of Business Development at ReCode Therapeutics
- **—** — Chief Business Officer at Callio Therapeutics, the multi-payload ADC company spun out of Hummingbird Bioscience
- **2025-06** — Joined the Board of Directors of Ability Biotherapeutics as an independent director
- **2025-12** — Appointed Ability Biotherapeutics' first Chief Business Officer

## Achievements

- Appointed the first Chief Business Officer of Ability Biotherapeutics in December 2025
- Led or supported numerous in- and out-licensing transactions from early-stage research technologies to clinical-stage assets
- Held business development and corporate venture leadership roles across both emerging biotechs and global pharma over 20+ years
- Board Chair of Canadian Entrepreneurs in Life Sciences (CELS), a non-profit supporting emerging sector leaders
- Earned a Ph.D. in Biological Chemistry from Stanford University after a B.Sc. from the University of Winnipeg

## Latest updates

- **2025-12** — Named Chief Business Officer of Ability Biotherapeutics, leading business development, global partnering and investor relations.
- **2025-06** — Joined the Board of Directors of Ability Biotherapeutics as an independent director.

## Links

- Website: https://ability.bio
- LinkedIn: https://www.linkedin.com/in/angele/

---

Profile page: https://yespress.io/angele-maki
Published by YesPress — https://yespress.io
Last updated: 2026-06-25